ScotiaBank Lifts AbbVie Price Target to $320 as Stock Trades Near 52-Week High

By TrendSpider Editor

The forward setup for AbbVie heading into the remainder of 2026 looks constructive from a technical standpoint, but the concentration risk around key franchises and ongoing biosimilar competition in the immunology space remain important considerations. The fact that ScotiaBank did not issue a new up

ScotiaBank Lifts AbbVie Price Target to $320 as Stock Trades Near 52-Week High

Key Drivers of the ABBV Stock Move

• Main Catalyst: ScotiaBank's Louise Chen confirmed a buy rating on AbbVie and raised her price target from $280 to $320, a $40 increase that now sits well above the current market price of $267.62.
• Bull Case: The revised $320 price target represents meaningful upside from current levels, and the fact that ScotiaBank is lifting its target while shares trade near the 52-week high of $269.39 suggests the analyst sees fundamental justification for a continued breakout rather than a near-term pullback.
• Bear Case: At $267.62, ABBV is trading within striking distance of its 52-week high of $269.39, leaving limited technical cushion. Investors chasing the stock at these levels take on heightened risk if the broader market or sector rotates, and a single analyst reaffirmation without an upgrade in rating may not be enough to sustain momentum on its own.

The forward setup for AbbVie heading into the remainder of 2026 looks constructive from a technical standpoint, but the concentration risk around key franchises and ongoing biosimilar competition in the immunology space remain important considerations. The fact that ScotiaBank did not issue a new upgrade, but rather chose to hold a buy rating and widen its price target gap significantly, suggests growing confidence in AbbVie's pipeline execution and near-term revenue visibility. Investors will be watching closely for any updated commentary around the company's growth-stage assets as the stock attempts to establish new highs.

ABBV Analyst Ratings and Price Targets

ScotiaBank analyst Louise Chen confirmed a buy rating on AbbVie on October 6, 2026, while raising her price target from $280 to $320. The average price target across covering analysts currently stands at $320, aligning precisely with ScotiaBank's revised figure. No upgrades or downgrades were issued in conjunction with this action.

ABBV Seasonality

October has historically been an active period for pharmaceutical sector re-ratings as analysts recalibrate models ahead of year-end earnings cycles. For a large-cap name like AbbVie, fourth-quarter analyst activity often sets the tone for institutional positioning heading into January.

ABBV Relative Performance

AbbVie's current price of $267.62 places it just 0.66% below its 52-week high of $269.39, meaningfully outperforming peers that have faced greater headwinds from patent cliffs and pipeline uncertainty. With the 52-week low sitting at $191, the stock has traveled a range of more than $78 over the past year, reflecting strong long-term appreciation that continues to attract analyst attention at elevated price levels.